Abeona Therapeutics Inc. (NASDAQ: ABEO) director Christine Berni Silverstein executed a sale of 18,160 shares of common stock on June 15, 2026, totaling $103,695 in value. The transactions were conducted across multiple trades at prices ranging from $5.68 to $5.73 per share. Executed at a weighted average price of $5.7101 per share, the divestment left Silverstein with a direct holding of 119,562 shares in the biotechnology company.
The sale was explicitly linked to covering tax obligations associated with the vesting of restricted stock awards. At the time of reporting, Abeona's stock was trading at $5.67, marking an 11.6% gain over the previous six months and indicating recent upward momentum for the firm. Independent analysis indicates that Abeona may be undervalued at present levels, supported by a balance sheet where cash holdings surpass debt obligations.
In parallel with the insider transaction, Abeona Therapeutics reported its first-quarter 2026 earnings, delivering results that exceeded market expectations. The company recorded an earnings per share of -$0.30, outperforming the forecasted loss of -$0.34. Revenue also significantly surpassed projections, coming in at $8.72 million against a forecast of $4.62 million. Despite these positive financial metrics, the stock experienced a decline during pre-market trading, highlighting a divergence between reported financial performance and immediate market reaction.